Slingshot members are tracking this event:

Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis; Topline Results for Phase 3 ATMOS-1 and ATMOS-2 Clinical Trials Expected in 2Q 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
DERM Community voting in process

Additional Information

Additional Relevant Details Dermira now expects to announce topline efficacy and safety data for both of these trials during the second quarter of 2016, compared with previous guidance of mid-2016.
“Once again, we are delighted to announce the completion of patient enrollment, ahead of schedule, in a Dermira clinical program, this time for our two Phase 3 DRM04 pivotal clinical trials in hyperhidrosis,” stated Luis Peña, chief development officer of Dermira.  “We continue to believe that DRM04, a topically administered anticholinergic, may provide an attractive therapeutic approach, if approved, relative to the currently available treatment options for patients suffering from hyperhidrosis. We look forward to sharing the results from our Phase 3 trials in the coming months.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 01, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Atmos-1, Atmos-2, Dermatologic Diseases, Drm04, Axillary Hyperhidrosis